Marc Humbert
Overview
Explore the profile of Marc Humbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
877
Citations
37416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hoeper M, Rosenkranz S, Badesch D, Humbert M, Langleben D, McConnell J, et al.
Respir Med
. 2024 Dec;
236:107910.
PMID: 39667586
Background: Risk stratification is an essential part of evaluating disease severity in patients with pulmonary arterial hypertension (PAH). This study applied the 4-strata COMPERA 2.0 risk model to the Phase...
12.
Gomberg-Maitland M, Badesch D, Gibbs J, Grunig E, Hoeper M, Humbert M, et al.
J Heart Lung Transplant
. 2024 Dec;
PMID: 39645016
Background: This analysis examined the effects of the activin signaling inhibitor, sotatercept, in pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI). Methods: Pooled data from PULSAR (N ...
13.
Kovacs G, Humbert M, Avian A, Lewis G, Ulrich S, Vonk Noordegraaf A, et al.
Eur Respir J
. 2024 Nov;
64(6).
PMID: 39603672
Background: Exercise pulmonary hypertension (PH) was defined by a mean pulmonary arterial pressure (mPAP)/cardiac output (CO) slope >3 mmHg·min·L between rest and exercise in the 2022 European Society of Cardiology/European...
14.
Poisson C, Hlavaty A, Favrolt N, Chaumais M, Grynblat J, Jutant E, et al.
Chest
. 2024 Nov;
PMID: 39571726
Background: Trastuzumab emtansine has been recently suspected to be associated with the development of pulmonary arterial hypertension (PAH). Research Question: Is there an association between trastuzumab, trastuzumab emtansine, or trastuzumab...
15.
McLaughlin V, Humbert M
Circulation
. 2024 Nov;
150(21):1653-1655.
PMID: 39556653
No abstract available.
16.
Stourm L, Grynblat J, Savale L, Lacoste-Palasset T, Jais X, Coulet F, et al.
Eur Respir J
. 2024 Nov;
65(3).
PMID: 39510553
Background: Pulmonary hypertension (PH) is an unusual complication of X-linked disease caused by loss-of-function (LOF) variants in the filamin A () gene. Patients with LOF may also present dysmorphic facial...
17.
Transcriptome analyses reveal common immune system dysregulation in PAH patients and -deficient rats
Ruffenach G, Le Ribeuz H, Dutheil M, El Jekmek K, Dumont F, Willer A, et al.
Pulm Circ
. 2024 Oct;
14(4):e12434.
PMID: 39444497
Pulmonary arterial hypertension (PAH) is a severe disease caused by progressive distal pulmonary artery obstruction. One cause of PAH are loss-of-function mutations in the potassium channel subfamily K member 3...
18.
Sitbon O, Skride A, Feldman J, Sahay S, Shlobin O, McLaughlin V, et al.
Lancet Respir Med
. 2024 Sep;
12(11):865-876.
PMID: 39307144
Background: The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data strongly indicating involvement in disease pathogenesis; however, clinical studies have yielded...
19.
Humbert M, Hassoun P, Chin K, Bortman G, Patel M, La Rosa C, et al.
Eur Respir J
. 2024 Sep;
64(5).
PMID: 39255991
Background: MK-5475 is an investigational inhaled soluble guanylate cyclase stimulator hypothesised to avoid most side-effects of systemic vasodilation. Methods: The phase 2 INSIGNIA-PAH (NCT04732221) trial randomised adults with pulmonary arterial...
20.
Escal J, Poenou G, Delavenne X, Bezzeghoud S, Mismetti V, Humbert M, et al.
Blood Rev
. 2024 Sep;
68:101240.
PMID: 39245607
The use of oral anticoagulants in the management of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) presents distinct therapeutic challenges and benefits. In PAH, the benefits of...